• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Español
  • English
  • Bloglovin
  • Email
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
CDE Almería – Centro de Documentación Europea – Universidad de Almería

CDE Almería - Centro de Documentación Europea - Universidad de Almería

Centro de Documentación Europea de la Universidad de Almería

  • HOME
  • WHAT´S ON
    • EU BULLETINS
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
    • EU official journal
  • ABOUT US
    • Presentation
    • People
    • Contact

Imminent anti-metastatic vaccine for prostate cancer

Inicio » EU News » Imminent anti-metastatic vaccine for prostate cancer

08/03/2019

Prostate cancer is the most commonly diagnosed cancer in men with millions of new cases every year. European scientists have developed a novel vaccine to prevent disease metastasis, the main cause of mortality amongst advanced prostate cancer sufferers.


The majority of prostate cancer patients are diagnosed at the localised, pre-metastatic stage of the disease. They have to undergo primary tumour excision by surgery or radiotherapy followed by active monitoring to ensure cancer relapse doesn’t occur. Despite the frequent incidence of metastasis formation, there is currently no treatment available post-surgery to directly limit micro-metastasis formation.

Available treatments exhibit serious side effects, mainly focus on later stages of cancer progression and almost always develop resistance. There is an urgent need for therapeutic strategies that act early on in prostate cancer before cancer returns and cancer cells start to spread, making the treatment far more difficult and expensive.

Clinical impact

So far, the vaccine has been tested in prostate cancer patients after removal of the primary tumour and before metastasis formation to address the challenge posed by the high incidence of metastasis following primary tumour excision. Results from the phase I/II clinical trial, which involved 22 patients after prostatectomy, demonstrated the excellent tolerability and safety of RV001. Importantly, the majority (86 %) of patients showed a significantly positive immune response.

As Dr Borghei outlines: “the next step is to validate the efficacy of the drug in a Phase IIb clinical trial in a larger number of patients.″ Nonetheless, she emphasises the need for partnerships and capital investment to secure successful commercialisation of the vaccine.

RV001 has the potential to be administered to more than 150 000 patients in Europe and US alone, helping them at an early stage to reduce prostate cancer burden. This will bring in an estimated revenue of EUR 1 billion by 2030.

RV001 holds important competitive advantages such as targeting a stage of the disease where there is currently no treatment available coupled with high safety and cost-effectiveness. At the same time, scientists are confident it will work against multiple types of metastatic cancer.

More Information

Access to the full new

Publicaciones relacionadas:

New technology is recognising affective states €2 billion to fast forward the creation of the European Innovation Council Epigenetic therapy! Switching off your own cancer genes New intraoperative probe for breast cancer tissue R&I cooperation between EU and Middle East reaches new heights

“This is a space for debate. All comments, for or against publication, that are respectful and do not contain expressions that are discriminatory, defamatory or contrary to current legislation will be published”.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Publicaciones relacionadas

New technology is recognising affective states €2 billion to fast forward the creation of the European Innovation Council Epigenetic therapy! Switching off your own cancer genes New intraoperative probe for breast cancer tissue R&I cooperation between EU and Middle East reaches new heights

Footer

Centro de Documentación Europea de Almería
CDE Almería

Edificio Parque Científico-Tecnológico (Pita) Planta: 1ª, Despacho: 29
04120 – Ctra. Sacramento s/n.
Almería (Spain)
Teléfono: (+34) 950 015266

Sing in!

Navigation

  • HOME
  • WHAT´S ON
    • EU BULLETINS
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
    • EU official journal
  • ABOUT US
    • Presentation
    • People
    • Contact

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright © 2022 CDE Almería · Legal terms · Privacy policy · Cookies policy